Dabur Research Foundation
Ghaziabad, India· Est.
A full‑service Indian CRO delivering rapid, high‑quality preclinical research for global pharma and biotech.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
A full‑service Indian CRO delivering rapid, high‑quality preclinical research for global pharma and biotech.
OncologyMetabolic & Endocrine DisordersGastrointestinal & Digestive HealthNeurology & Neurodegenerative DisordersWomen's HealthDermatology & Skin HealthAnti‑Microbial & Anti‑Viral TestingRegenerative MedicineEx‑Vivo Models
Technology Platform
Custom in‑vitro, ex‑vivo, and in‑vivo disease models combined with DMPK, toxicology, analytical bio‑analytical testing, and regulatory consulting, all under GLP‑AAALAC‑ISO quality standards.
Opportunities
Expansion into AI‑driven drug repurposing and increased outsourcing demand from global pharma for rapid, cost‑effective preclinical data.
Risk Factors
Intense competition from larger global CROs and the need to continuously upgrade infrastructure to meet evolving regulatory standards.
Competitive Landscape
Competes with Indian CROs like Syngene and GVK Biosciences and global players such as Charles River; differentiates through expertise in traditional medicine and a strict no‑conflict policy.